Healthcare News by GLG Council Members

Ken PowellPresidentGenesis Business Development, LLC

Sequenom Sees Q4 11 Percent Revenue Drop

March 18, 2010

Sequenom reported that Q4 revenue dropped 11%.  The cause of this steep decline in sales were due to weak sales in its MassArray equipment and associated products.  Sequenom continues to focus its resources on its molecular diagnostics test for Down's syndrome.

Wockhardt's Secured lenders Getting Jittery !!!!!

March 17, 2010

Analysis by: GLG Expert Contributor

Analysis of:Secured lenders insecure over Wockhardt's plan- Pharmaceuticals-Healthcare/Biotech-News By Industry-News-The Economic Times | economictimes.indiatimes.com

In the ongoing saga of Wockhardt - assets sale - secured lenders & unsecured lenders.Secured lenders have clearly lost hopes or don't see light at the end of the tunnel!!!The recent change of stance in Bombay High Court by ICICI - led consortium of Secured lenders is an indication that hopes of revival of the company are being lost!!!The Company has been substantial decrease in business in recent times.

Indian Pharma market coming of Age!!!!

March 17, 2010

Analysis by: GLG Expert Contributor

Analysis of:Global pharma majors plans aggressive expansion in India | beta.profit.ndtv.com

Indian pharma market & industry has been more of a provider of service to markets & consumers.But in recent time of pricing pressures in the Western world, increased Generic competetion & regulatory hurdles pharma companies now look at India as a favorable market.The growth potential in India is tremendous as we witness development of Healthcare sector from unorganized to Organized sector.

Nature jobs - a look to the future ahead of time

March 16, 2010

Analysis by: GLG Expert Contributor

Nature jobs.com is the premier science recruitment website listing > 6000 jobs across all scientific disciplines from both academic and commercial research centers. Its free, making it the site of choice for many institutions.

Relationship between Big Pharmaceuticals and the Indian Pharmaceuticals

March 15, 2010

Analysis by: GLG Expert Contributor

Analysis of:AstraZeneca inks pact with Torrent for supply of branded generics | www.pharmabiz.com

As Indian pharmaceuticals move up the value chain, the natural progression is from “collaboration” to “cooperation” between big pharmaceutical and the Indian companies. Cooperation is the only strategy left for the big pharmaceuticals to expand rapidly. It will be interesting where this leads.

Accelerated Partial Breast Irradiation (APBI) - key players

March 12, 2010

Analysis by: GLG Expert Contributor

Analysis of:A new player in the growing Breast Brachytherapy field | www.senorx.com

The introduction of the SenoRx multi-lumen applicator for breast brachytherapy is not a new idea. It is, however, a market savvy approach but not the optimum brachytherapy application.

Increased cancer risks from CT scans

March 12, 2010

Analysis by: GLG Expert Contributor

Analysis of:Report Links Increased Cancer Risk to CT Scans | www.nytimes.com

The proliferation of CT imaging has increased exposure to radiation for both adult and pediatric patients. There are instances when CT imaging is used in lieu of a non-ionizing imaging alternative such as MRI or ultrasound. Application of any radiation producing technology must be considered in light of risk vs benefit and as is often the case, such decisions are made instead on the basis of expediency or protocol.

Ken PowellPresidentGenesis Business Development, LLC

OVA1 Will Receive Medicare Reimbursement

March 12, 2010

Vermillion announced today that Medicare will reimburse for the company's OVA1 test, which is available exclusively through Quest Diagnostics.  Highmark Medical Services is the CMS contractor that will process the claims.

Electronic Medical Records Taking Off Even Before the Money Starts to Flow

March 12, 2010

Analysis by: GLG Expert Contributor

Although the federal government will not pay a dime to either hospitals or physicians for meaningfully using electronic medical records prior to this October for hospitals and next January for physicians, there is already growing evidence that just the prospect of this is driving the health care industry toward adoption faster than originally anticipated.

Ken PowellPresidentGenesis Business Development, LLC

Orchid Cellmark's Q4 Revenues Rise 21 Percent

March 12, 2010

Orchid Cellmark posted a 21% increase in 4th quarter revenues.  Core forensic testing services in the US and UK drove this higher than expected growth.

Page : 12345678910Next1 to 10 of 8076